Aug 26, 2026 02:52PM
Aug 26, 2026 02:52PM
Aug 24, 2026 07:00AM
Jul 24, 2026 08:31AM
Jul 24, 2026 08:30AM
Jul 22, 2026 09:00AM
Jul 15, 2026 01:01AM FDA grants priority review to Genentech's Gazyva for kidney disease
Jul 15, 2026 01:00AM
Jul 2, 2026 01:10AM
Jun 30, 2026 01:09AM
Jun 30, 2026 01:09AM
Jun 18, 2026 01:00AM
Jun 18, 2026 01:00AM
Jun 11, 2026 01:05AM FDA grants priority review for Genentech's Tecentriq in stage III colon cancer
Jun 11, 2026 01:05AM
Jun 2, 2026 07:00AM
Jun 2, 2026 01:05AM
May 19, 2026 01:05AM
May 19, 2026 01:05AM
May 15, 2026 12:45PM
May 15, 2026 12:45PM FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Apr 30, 2026 01:00AM
Apr 24, 2026 02:49AM
Apr 22, 2026 08:30AM
Apr 21, 2026 07:15PM
Apr 21, 2026 11:45AM
Apr 21, 2026 01:00AM
Apr 16, 2026 07:00AM Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Mar 30, 2026 09:01AM
Mar 30, 2026 09:00AM
Mar 19, 2026 02:11PM
Mar 18, 2026 09:00AM
Mar 9, 2026 02:10AM
Mar 6, 2026 08:45AM
Mar 2, 2026 01:10AM Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
Feb 20, 2026 02:00AM
Feb 20, 2026 02:00AM
Feb 20, 2026 01:05AM
Feb 16, 2026 01:00AM
Feb 7, 2026 03:40PM
Dec 22, 2025 01:01AM
Dec 22, 2025 01:00AM FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
Dec 16, 2025 08:30AM
Dec 8, 2025 04:30PM
Nov 10, 2025 01:10AM
Nov 3, 2025 09:00AM
Nov 3, 2025 01:00AM
Oct 28, 2025 02:00AM
Oct 23, 2025 09:00AM Flatiron Health Announces 12 Abstracts Accepted to Be Presented at ISPOR Europe 2025
Oct 20, 2025 01:05AM

330,175 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All